These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 3873774)

  • 1. Separation of an active substance responsible for the factor VIII inhibitor bypassing activity in Autoplex.
    Fukui H; Fujimura Y; Sugimoto M; Okubo Y; Yoshioka A
    Nihon Ketsueki Gakkai Zasshi; 1985 Feb; 48(1):134-46. PubMed ID: 3873774
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison between two concentrates with factor VIII inhibitor bypassing activity.
    Vinazzer H
    Thromb Res; 1982 Apr; 26(1):21-9. PubMed ID: 6980497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation of prekallikrein activator from guinea pig serum or plasma adsorbed to immune precipitates or celite: possible relationship to Hageman factor.
    Treloar MP; Pyle H; Ozge-Anwar AH; Takeuchi Y; Movat HZ
    Eur J Immunol; 1972 Aug; 2(4):338-45. PubMed ID: 5083514
    [No Abstract]   [Full Text] [Related]  

  • 4. Conjectures on factor VIII bypassing activity.
    Aronson DL
    Prog Clin Biol Res; 1981; 72():103-21. PubMed ID: 6977778
    [No Abstract]   [Full Text] [Related]  

  • 5. Activation of factor IX by factor XIa--a spectrophotometric assay for factor IX in human plasma.
    Tans G; Janssen-Claessen T; van Dieijen G; Hemker HC; Rosing J
    Thromb Haemost; 1982 Oct; 48(2):127-32. PubMed ID: 6983739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of FEIBA (factor eight inhibitor bypassing activity) in cataract extraction in hemophilia A patient with inhibitor.
    Tourbaf KD; Dunlap BE; Ambrus JL; Rodman DJ; Atwal AJ
    J Med; 1982; 13(5-6):399-410. PubMed ID: 6820380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Inhibitor of the coagulating fraction of factor VIII in the puerperium].
    Avilés A; Rangel B; Reyna MP; Pizzuto J
    Ginecol Obstet Mex; 1986 Jun; 54():152-4. PubMed ID: 3089880
    [No Abstract]   [Full Text] [Related]  

  • 8. [A case of sigmoid cancer who acquired factor V inhibitor producibility and treated with factor VIII inhibitor bypassing activity preparation FEIBA--with bibliographic review (author's transl)].
    Abe T; Kazama M; Itokazu K; Kinoshita T; Ogushi T; Tahara C; Fukui H
    Rinsho Ketsueki; 1980 Nov; 21(11):1664-73. PubMed ID: 6782277
    [No Abstract]   [Full Text] [Related]  

  • 9. Thrombogenicity of antihemophiliac preparations with factor VIII inhibitor bypassing activity.
    Melewski DJ; Huebschmann J; Tourbaf K; Ambrus CM; Ambrus JL
    J Med; 1981; 12(2-3):89-96. PubMed ID: 6974212
    [No Abstract]   [Full Text] [Related]  

  • 10. Disseminated intravascular coagulation after infusion of FEIBA (factor VIII inhibitor bypassing activity) in a patient with acquired haemophilia.
    Rodeghiero F; Castronovo S; Dini E
    Thromb Haemost; 1982 Dec; 48(3):339-40. PubMed ID: 6984544
    [No Abstract]   [Full Text] [Related]  

  • 11. Purification and properties of human factor IXa.
    Váradi K; Elödi S
    Thromb Haemost; 1976 Jun; 35(3):576-85. PubMed ID: 10636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of active coagulation factors in Autoplex-T with colorimetric active site-specific assay technology.
    Lundblad RL; Bergstrom J; De Vreker R; Bray G; Gomperts E; Baker D; Kingdon HS; Mann KG; Hartshorn J; Jenny RJ
    Thromb Haemost; 1998 Nov; 80(5):811-5. PubMed ID: 9843176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The subunit structure of normal and hemophilic factor VIII.
    Shapiro GA; Andersen JC; Pizzo SV; McKee PA
    J Clin Invest; 1973 Sep; 52(9):2198-210. PubMed ID: 4199414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium-specific immunoassays for factor IX: reduced levels of antigen in patients with vitamin K disorders.
    Bray GL; Weinmann AF; Thompson AR
    J Lab Clin Med; 1986 Mar; 107(3):269-78. PubMed ID: 3485164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of clotting factor IX in plasma-derived preparations by electrophoretic techniques.
    Pock K; Buchacher A; Rizzi A; Josić D
    J Chromatogr A; 2001 Jun; 921(1):57-67. PubMed ID: 11461014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Increase of in vitro factor VIII activity by polyaminopolycarboxylic acid].
    Drawert J; Stein P
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1980; 107(6):914-8. PubMed ID: 6162758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of phospholipid on factor VIII inactivation.
    Barrowcliffe TW; Kemball-Cook G; Gray E
    Prog Clin Biol Res; 1984; 150():251-63. PubMed ID: 6431431
    [No Abstract]   [Full Text] [Related]  

  • 18. A comparison between a serum fraction and FEIBA fraction in haemophilia.
    Hutton RA; Dormandy K; Nour-Eldin F
    New Istanbul Contrib Clin Sci; 1980; 13(1):9-22. PubMed ID: 6774316
    [No Abstract]   [Full Text] [Related]  

  • 19. Purification of human factor IX by chromatography of a coagulation factor concentrate.
    Suomela H
    Thromb Haemost; 1976 Feb; 35(1):211-21. PubMed ID: 989188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII.
    Lusher JM; Blatt PM; Penner JA; Aledort LM; Levine PH; White GC; Warrier AI; Whitehurst DA
    Blood; 1983 Nov; 62(5):1135-8. PubMed ID: 6414555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.